U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29N9
Molecular Weight 467.5688
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMREDOBRESIB

SMILES

CNC1=NC(=CN2C(C)=NN=C12)C3=NC4=C(C=C(C=C4)N5CCN(C)CC5)N3CC6=CC=CC=C6

InChI

InChIKey=JLUUVUUYIXBDCG-UHFFFAOYSA-N
InChI=1S/C26H29N9/c1-18-30-31-26-24(27-2)28-22(17-34(18)26)25-29-21-10-9-20(33-13-11-32(3)12-14-33)15-23(21)35(25)16-19-7-5-4-6-8-19/h4-10,15,17H,11-14,16H2,1-3H3,(H,27,28)

HIDE SMILES / InChI
Molecular Formula C26H29N9
Molecular Weight 467.5688
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
149124
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.47 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.39 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.04 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
1.5 mg 1 times / day steady-state, oral
dose: 1.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8.07 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.48 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.94 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2.5 mg 1 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
31.5 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
1.5 mg single, oral
dose: 1.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
53.9 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.39 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
1.5 mg 1 times / day steady-state, oral
dose: 1.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
94.4 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2 mg 1 times / day steady-state, oral
dose: 2 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
51.5 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
87 nM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/37556913/
2.5 mg 1 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
AMREDOBRESIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Substance Class Chemical
Created
by admin
on Tue Apr 01 23:06:27 GMT 2025
Edited
by admin
on Tue Apr 01 23:06:27 GMT 2025
Record UNII
F6XR3O34V2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BI-894999
Preferred Name English
AMREDOBRESIB
INN  
Official Name English
amredobresib [INN]
Common Name English
BI894999
Code English
1,2,4-TRIAZOLO(4,3-A)PYRAZIN-8-AMINE, N,3-DIMETHYL-6-(6-(4-METHYL-1-PIPERAZINYL)-1-(PHENYLMETHYL)-1HBENZIMIDAZOL-2-YL)
Systematic Name English
6-(1-BENZYL-6-(4-METHYLPIPERAZIN-1-YL)-1H-1,3-BENZODIAZOL-2-YL)-N,3-DIMETHYL-(1,2,4)TRIAZOLO(4,3-A)PYRAZIN-8-AMINE
Systematic Name English
Code System Code Type Description
FDA UNII
F6XR3O34V2
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
NCI_THESAURUS
C160257
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
PUBCHEM
76072013
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
CAS
1610044-98-8
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
SMS_ID
300000033364
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
INN
11965
Created by admin on Tue Apr 01 23:06:27 GMT 2025 , Edited by admin on Tue Apr 01 23:06:27 GMT 2025
PRIMARY
Related Record Type Details
BROMODOMAIN TESTIS-SPECIFIC PROTEIN
TARGET -> INHIBITOR
BRDT(BD1) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 3
TARGET -> INHIBITOR
BRD3(BD2) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 3
TARGET -> INHIBITOR
BRD3(BD1) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 4
TARGET -> INHIBITOR
BRD4(BD1) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 4
TARGET -> INHIBITOR
INHIBITS BRD4(BD1) BINDING TO ACETYLATED HISTONES
IC50
BROMODOMAIN TESTIS-SPECIFIC PROTEIN
TARGET -> INHIBITOR
BRDT(BD2) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 2
TARGET -> INHIBITOR
BRD2(BD2) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 4
TARGET -> INHIBITOR
BRD4(BD2) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 2
TARGET -> INHIBITOR
BRD2(BD1) DOMAIN
Kd
BROMODOMAIN-CONTAINING PROTEIN 4
TARGET -> INHIBITOR
INHIBITS BRD4(BD2) BINDING TO ACETYLATED HISTONES
IC50
Related Record Type Details
Structure of AMREDOBRESIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966